INMB (INmune Bio Inc) Net Profit

INMB (INmune Bio) - company brandmark

INmune Bio, Inc. (INMB) is developing selective TNF inhibitors to combat dementia. The company's current profit levels help identify hidden margin risks, with the latest figure standing at -0.02. The financial foundation relies on government funding for the immunotherapy of inflammatory pathologies. The development of the DN-TNF pipeline for cancer and Alzheimer's therapy ensures active business growth without systemic immune suppression.

INMB (INmune Bio, Inc.) Net Profit history from 07/04/2022 to 10/29/2026

Analytical breakdowns and data insights for company INmune Bio (INMB)

- price and consensus price forecast:
Stock Quotes INmune Bio Corporation|INMB - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization INmune Bio Corporation|INMB - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share INmune Bio|INMB - Book Capitalization|Market Capitalization to Book Value inmunebio.com|INMB - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio INmune Bio, Inc.|INMB - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio INmune Bio Inc|INMB - Company Total Debt|Debts to Book Capitalization INmune Bio Corporation|INMB - Company Long-Term Debt|Company Short-Term Indebtedness INmune Bio|Immediate Liquidity inmunebio.com
- net income and valuation multiples indicators:
INMB - Net Profit
Summary company analysis:INmune Bio, Inc.
Core merchandise of INmune Bio Corp

INmune Bio, Inc. (INMB) investments in the development of selective TNF inhibitors for Alzheimer's therapy and oncology drive the high capital intensity of its current growth phase. By analyzing the company's income and expense balance, an investor can discern a net financial result that strips the real business value of market noise, allowing for the tracking of operational model sustainability and accumulated capital dynamics amidst clinical trials.

Main competitors

Net Income argenx BVBA|BNTX (BioNTech SE) - Net Profit|Net Profit Abivax Pharma|Net Income ADMA (ADMA Biologics, Inc.)|PTGX (Protagonist Therapeutics, Inc.) - Final Profit|Net Profit IMVT (Immunovant Corp)|Net Financial Result Kiniksa Corp (KNSA)|GRFS - Company Net Income|adaptivebiotech.com (ADPT) - Net Income|Celldex Therapeutics, Inc. (CLDX) - Company Net Income|Net Income Aurinia Pharmaceuticals Inc|Net Income BCRX|Net Profit Vera Corp|Company Net Income Dianthus Therapeutics (DNTH)|pharvaris.com - Company Profit|Net Profit ABCL (AbCellera Biologics Inc)|Tourmaline Bio Inc (TRML) - Company Net Income|Intrexon - Net Profit|Net Financial Result Pharming Corp PHAR|Nektar Therapeutics (NKTR) - Company Net Income|Company Profit UPB|Company Net Income Zenas Biopharma|Net Income Immunome Inc (IMNM)|Net Income GOSS (Gossamer Corp)|Net Profit KalVista Corp (KALV)|Company Net Income Septerna Inc SEPN|PVLA: Company Profit|Savara - Net Profit|Company Net Income Rigel Pharma|ANAB (AnaptysBio Corp) - Net Income|Astria Corp - Final Profit|ENGN (enGene Holdings Inc.) - Net Profit|Company Net Income RAPT|Net Profit JBIO|Net Financial Result Aclaris Therapeutics Inc.|Company Net Income Kyverna KYTX|Tiziana Life Sciences, Ltd. (TLSA) - Company Net Income|CABA: Net Income|Final Profit VTYX (ventyxbio.com)|THTX: Net Profit|AVTX - Net Financial Result|Company Net Income Eledon|Company Profit AGEN (Agenus, Inc)|Net Profit CLYM|Net Income zurabio.com ZURA|aTyr Pharma - Net Income|Net Financial Result Adagene Inc (ADAG)|Ikena Oncology, Inc. - Net Profit|Net Financial Result Shattuck Labs, Inc. STTK|equilliumbio.com (EQ) - Company Net Income|Company Profit CNTB|Company Net Income Immunic Therapeutics|Net Income Atara Biotherapeutics Inc (ATRA)|Net Profit IFRX|Company Net Income XFOR (X4 Pharmaceuticals, Inc)|Company Net Income Adicet Bio, Inc. ACET|CELU (Celularity Inc) - Profit After Tax|Barinthus Biotherapeutics plc - Net Profit|Final Profit KZR (Kezar Life Sciences Inc.)|SABS: Net Profit|Akari Therapeutics, Plc (AKTX) - Net Profit|Company Net Income Enlivex Therapeutics Ltd|QTTB: Final Profit|Company Net Income GeoVax (GOVX)|Net Income Edesa Biotech Inc EDSA|Net Profit IBIO (iBio Corp)|Net Profit Carisma Therapeutics Inc CARM|XTLB: Net Income|Final Profit BOLT (Bolt Biotherapeutics)|HCWB: Net Profit|APVO - Net Financial Result|Company Net Income AIM ImmunoTech|Net Income Aditxt Corp (ADTX)|Company Net Income GRI Bio, Inc. (GRI)|Net Income xortx.com XRTX|Vyome Holdings - Net Income|Net Profit Revelation Biosciences Inc REVB|INDP - Company Net Income|SCNI (BiondVax Pharmaceuticals) - Company Profit|CALI: Net Profit|Company Net Income Affimed N.V. (AFMD)|ALLK (Allakos Inc) - Net Profit|HOOKIPA (HOOK) - Net Financial Result|Company Net Income IGM Biosciences, Inc. (IGMS)|iTeos Pharma - Company Profit|Company Net Income Ocean Biomedical, Inc. OCEA|TCBP - Net Income|THRD: Net Income